Immunovant reports Q1 fiscal 2026 results, says IMVT-1402 timelines on track
The company reported cash of $797.8 million as of June 30, 2026, and said all six IMVT-1402 disease programs remain on schedule.
SEC filing
Latest
3 stories
Thursday, August 6
OmniAb raises 2026 revenue and cash guidance on partner pipeline momentum
Several OmniAb-derived antibody programs advanced in the quarter, including a Phase 3 start for Johnson & Johnson's ramantamig and new Phase 2b plans for Teva's TEV-'408 in vitiligo.
SEC filing
Roivant reports Q1 fiscal 2027 results, pipeline on track across four vants
Roivant said brepocitinib launch prep for dermatomyositis remains on schedule, three trial readouts are due in the second half of 2026, and it holds $3.9 billion in cash and securities.
SEC filing